Skip to main content

Advertisement

SpringerLink
Log in

CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22)

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The translocation t(16;21)(p11;q22) is rare, occurs with an incidence of 1%, in acute myeloid leukemia (AML), forming TLS/FUS-ERG fusion transcript, and it is known to cause the hemophagocytosis and vacuolation of leukemic cells. As previously reported cases numbered less than 60, we aimed to identify the clinical and genetic aspects of AML with t(16;21). Among 1,277 patients diagnosed with de novo and secondary AML, 12 AML patients with t(16;21) were retrospectively evaluated (0.94%, 12/1,277). AML with t(16;21) expressed CD56 with a median value of 45% (7.8–87%), and the rate of hemophagocytosis plus vacuolation of leukemic cells was 2.9% (2.0–9.0%). CD56 antigen expression showed a correlation with the total rate of hemophagocytosis plus vacuolation, with a correlation coefficient of 0.663 (P = 0.019). AML with t(16;21) expressed CD13, CD33, CD34, CD117, CD56, HLA-DR, and cytoplasmic myeloperoxidase. RUNX1, which regulates a gene for hematopoiesis, is frequently mutated in AML and, in this study, one out of three patients showed the mutation R174Q in RUNX1. All of these 3 patients showed the fusion transcript TLS/FUS-ERG, which was detected by multiplex or nested PCR. AML with t(16;21) showed a very low rate of complete remission after induction chemotherapy (8.3%), and high relapse (75%) and mortality (75%) rates. AML with t(16;21) exhibited a distinct morphology with frequent CD56 expression and a poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Morgan R, Riske CB, Meloni A, Ries CA, Johnson CH, Lemons RS, et al. t(16;21)(p11.2;q22): a recurrent primary rearrangement in ANLL. Cancer Genet Cytogenet. 1991;53:83–90.

    Google Scholar 

  2. Imashuku S, Hibi S, Sako M, Lin Y-W, Ikuta K, Nakata Y, et al. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22). Cancer. 2000;88:1970–5.

    Article  CAS  PubMed  Google Scholar 

  3. Kong X-T, Ida K, Ichikawa H, Shimizu K, Ohki M, Maseki N, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood. 1997;90:1192–9.

    CAS  PubMed  Google Scholar 

  4. Bona ED, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87:250–6.

    PubMed  Google Scholar 

  5. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia. Blood. 1997;90:1643–8.

    CAS  PubMed  Google Scholar 

  6. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161–4.

    Article  CAS  PubMed  Google Scholar 

  7. Shikami M, Miwa H, Nishi K, Takahashi T, Shiku H, Tsutani H, et al. Myeloid differentiation antigen and cytokine receptor expression on acute myeloid leukemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor alpha chain. Br J Haematol. 1999;105:711–9.

    Article  CAS  PubMed  Google Scholar 

  8. Cho B-S, Min C-K, Eom K-S, Kim Y-J, Kim H-J, Lee S, et al. Feasibility of NIH consensus criteria for chronic graft versus host disease. Leukemia. 2009;23:78–84.

    Article  PubMed  Google Scholar 

  9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 109–47.

  10. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: an international system for human cytogenetic nomenclature. Basel: Karger; 2009.

  11. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood. 2007;110:1308–16.

    Article  CAS  PubMed  Google Scholar 

  12. Strehl S, Konig M, Mann G, Haas OA. Multiplex reverse transcriptase polymerase chain reaction screening in childhood acute myeloid leukemia. Blood. 2001;97:805–8.

    Article  CAS  PubMed  Google Scholar 

  13. Foadi MD, Slater AG, Pegrum GD. Erythrophagocytosis by acute lymphoblastic leukaemic cells. Scand J Haematol. 1978;20:85–7.

    Article  CAS  PubMed  Google Scholar 

  14. Shanley JD, Cline MJ. Phagocytosis of hematopoietic cells by blast cells in blast crisis of chronic myelocytic leukemia. West J Med. 1977;126:139–41.

    CAS  PubMed  Google Scholar 

  15. Spivak JL. Phagocytic tumor cells. Scand J Haematol. 1973;11:253–6.

    Article  CAS  PubMed  Google Scholar 

  16. Utzsinger PB, Yount WJ, Fuller CR, Logue MJ, Orringer EP. Hairy cell leukemia: B lymphocyte and phagocytic properties. Blood. 1977;49:19–23.

    Google Scholar 

  17. Savage DG, Zipin D, Bhagat G, Alobeid B. Hemophagocytic, non-secretary multiple myeloma. Leuk Lymphoma. 2004;45:1061–4.

    Article  PubMed  Google Scholar 

  18. Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, et al. Acute myeloid leukemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia. 2008;22:1567–8.

    Article  CAS  PubMed  Google Scholar 

  19. Kim JW, Park TS, Song JW, Lee KA, Hong DJ, Min YH, et al. Detection of FUS-ERG chimeric transcript in two cases of acute myeloid leukemia with t(16;21)(p11.2;q22) with unusual characteristics. Cancer Genet Cytogenet. 2009;194:111–8.

    Article  CAS  PubMed  Google Scholar 

  20. Ikushima S, Yoshihara T, Matsumura T, Misawa S, Morioka Y, Hibi S, et al. Expression of CD56/NCAM on hematopoietic malignant cells. Int J Hematol. 1991;54:395–403.

    Google Scholar 

  21. Song W-J, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166–75.

    Article  CAS  PubMed  Google Scholar 

  22. Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C. New mechanism of AML1 gene alteration in hematological malignancies. Leukemia. 2003;17:9–16.

    Article  CAS  PubMed  Google Scholar 

  23. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352–61.

    Article  CAS  PubMed  Google Scholar 

  24. Auewarakul CU, Leecharendkeat A, Tocharoentanaphol C, Promsuwicha O, Sritana N, Thongnoppakhun W. AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia: redundancy or synergism. Haematologica. 2007;92:861–2.

    Article  CAS  PubMed  Google Scholar 

  25. Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M, et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 2007;26:1163–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the “Development of Core Components in Bio-robot System (10024719)” under the ‘Industrial Source Technology Development Programs’ of the Ministry of Knowledge Economy (MKE) of Korea.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, 505 Seocho-gu, Banpo-dong, Seoul, 137-701, Korea

    Dong Wook Jekarl, Myungshin Kim, Jihyang Lim, Yonggoo Kim & Kyungja Han

  2. Department of Hospital Pathology, The Catholic University of Korea, Seoul, Korea

    Ah-Won Lee

  3. Catholic Hemopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, Korea

    Hee-Je Kim & Woo-Sung Min

Authors
  1. Dong Wook Jekarl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myungshin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jihyang Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yonggoo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyungja Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ah-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hee-Je Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Woo-Sung Min
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yonggoo Kim.

Additional information

D. W. Jekarl and M. Kim contributed equally to this work.

About this article

Cite this article

Jekarl, D.W., Kim, M., Lim, J. et al. CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22). Int J Hematol 92, 306–313 (2010). https://doi.org/10.1007/s12185-010-0650-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0650-5

Keywords

Search

Navigation